DESCRIBE-AD: A novel classification framework for atopic dermatitis

Chovatiya, Raj; Silverberg, Jonathan I.

doi:10.1016/j.jaad.2021.10.058

Cited by 7 publications

(4 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a recent post hoc analysis of the BREEZE-AD7 clinical trial, a phase III study that compared the efficacy of baricitinib 4 mg plus topical corticosteroids (TCS), with baricitinib 2 mg plus TCS and placebo plus TCS, has shown best results on signs (EASI 75) and symptoms (variations of itch-NRS of at least 4 points) in a clinical AD phenotype characterized by mild-to-moderate lesions (BSA up to 40%) and severe itch (itch-NRS > 7) [ 17 , 20 ]. As already mentioned, this phenotype is known as “itch-dominant” [ 26 ] and appears to respond better to baricitinib compared with all the intention-to-treat population of the clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

Gargiulo,

Ibba,

Malagoli

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of patients with severe AD after being evaluated in several clinical trials. However, a few concerns have been raised regarding their long-term safety and the management of these drugs in real-world clinical practice. In this article we described the results of a Delphi consensus aimed at describing the knowledge on JAKi and focusing, in particular, on providing clinical recommendations for dermatologists in daily practice regarding the use of these drugs. Methods Twelve Italian dermatologists reviewed the most recent literature regarding the efficacy and safety profiles of JAKi and proposed 24 statements. Results Agreement was reached for statements focusing on three main topics: (1) place in therapy of JAKi in patients with moderate-to-severe AD; (2) effectiveness and safety of JAK inhibitors in different phenotypes; (3) different approaches to the management of patients treated with JAKi in clinical practice. The panel proposed several recommendations regarding all the statements. Conclusion Given the wide use of JAKi in clinical practice, it is crucial to establish a specific follow-up for each patient’s phenotype in order to achieve the best possible clinical outcome and minimize potential adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

Gargiulo,

Ibba,

Malagoli

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…In 2022, Chovatiya and Silverberg proposed a comprehensive framework to standardise the assessment of patients with AD and called it DESCRIBE-AD, an acronym that stands for assessments of Dermatitis morphology and phenotype, Evolution of disease, Symptom severity, Comorbid health disorders, Response to therapy, Intensity of lesions, Burden of disease and Extent of lesions in AD. The framework helps characterise the heterogeneity of AD and inform therapeutic stratification [69].…”

Section: Patient Profiles In Admentioning

confidence: 99%

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis

Amerio,

Ferrucci,

Galluzzo

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that is frequently associated with a plethora of comorbidities. AD is, therefore, considered a systemic disease impacted by a considerable burden and leading to poor quality of life, especially in patients with moderate-to-severe disease. Since atopic and non-atopic comorbidities can further worsen the disease course, accurate establishment of the patient's individual intrinsic risk profile and needs is crucial and may help in guiding the selection of the best treatment option. Better quality of care for patients with AD can be delivered through a multidisciplinary team led by a dermatologist, for comprehensive patient management. The implementation of a multidisciplinary approach for AD could enhance the delivery of optimised and safe treatments, improve the standard of care and patient outcomes in the short and long term, and prevent or delay the lifelong impact of uncontrolled AD. Understanding the unmet needs, assessing

show abstract

“…In Europe and the United States, approximately 20% of children and 7–14% of adults suffer from AD [ 3 ], and the prevalence is continuously increasing. Various symptoms, including skin dryness, eczema, pruritus, and cracking, severely interfere with the quality of life of AD patients [ 4 , 5 ]. An imbalance between CD4 + T helper type 1 (Th1) and CD4 + T helper type 2 (Th2) cells mainly mediates the inflammation in AD [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Ozonated Sunflower Oil (OSO) Alleviates Inflammatory Responses in Oxazolone-Induced Atopic Dermatitis (AD)-Like Mice and LPS-Treated RAW 264.7 Cells

Kim,

Lee,

Lee

et al. 2024

J. Microbiol. Biotechnol.

View full text Add to dashboard Cite

Ozone, a highly reactive oxidant molecule, is widely used as a complementary therapy for various skin diseases, including wound healing, pressure ulcers, diabetic foot, and infections. However, there is limited research on the effectiveness of ozone for atopic dermatitis (AD). Ozonated sunflower oil (OSO) is an active ingredient obtained from partially ozonated sunflower oil (SO). OSO markedly reduced the LPS-induced increase in IL-1β and nitric oxide (NO) levels in RAW 264.7 mouse macrophage cells. Oxazolone (OXZ) was applied to hairless mice to induce AD-like skin symptoms and immune response. OSO significantly alleviated the OXZ-induced increases in the number of infiltrating mast cells, epidermal thickness, AD symptoms, thymic stromal lymphopoietin (TSLP), and filaggrin, as well as the serum levels of NO, IgE, IL-1β, and TNF-α. Furthermore, OSO inhibited the IL-4/STAT3/MAPK pathway and the expression of NF-κB. Our results suggest that OSO treatment could relieve AD-mediated skin damage through its anti-inflammatory and antioxidant activities. Therefore, it can be used as a therapeutic agent against AD-related skin diseases.

show abstract

DESCRIBE-AD: A novel classification framework for atopic dermatitis

Cited by 7 publications

References 103 publications

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis

Ozonated Sunflower Oil (OSO) Alleviates Inflammatory Responses in Oxazolone-Induced Atopic Dermatitis (AD)-Like Mice and LPS-Treated RAW 264.7 Cells

Contact Info

Product

Resources

About